[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598791":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":68,"collaborators":71,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":24,"enrollmentInfo":83,"targetDuration":24,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":58,"whyStopped":24,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Corewell Health West","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dual antiplatelet therapy 1-Month followed by single antiplatelet therapy indefinitely","ACTIVE_COMPARATOR","Aspirin and Clopidogrel (Plavix) for 1-month post-procedure followed by Aspirin indefinitely.\n\nDual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg\u002Fday) (Plavix) and aspirin (81 mg or more\u002Fday). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more\u002Fday).",[13],"Drug: Clopidogrel (Plavix) Pharmacogenetic Test Reagents",{"label":15,"type":10,"description":16,"interventionNames":17},"Dual antiplatelet therapy 6-Month followed by single antiplatelet therapy indefinitely","Aspirin and Clopidogrel (Plavix) for 6-months post-procedure followed by Aspirin indefinitely.\n\nDual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg\u002Fday) (Plavix) and aspirin (81 mg or more\u002Fday). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more\u002Fday).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Clopidogrel (Plavix) Pharmacogenetic Test Reagents","Dual antiplatelet therapy (DAPT), defined as the use of Clopidogrel (75 mg\u002Fday) (clopidogrel) and aspirin (81 mg or more\u002Fday). Single antiplatelet therapy (SAPT), defined as the use of aspirin (81 mg or more\u002Fday).",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Vikram C Kashyap, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Stephen C Orey, MS","CONTACT","6163916660","Stephen.orey@corewellhealth.org",[36,57],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Henry Ford Hospital","NOT_YET_RECRUITING","Detroit","Michigan","48202-2608","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-83.04575,42.33143,{"lat":48,"lon":47},[51,55],{"name":52,"role":32,"phone":53,"phoneExt":24,"email":54},"Sarah Meehan","(313) 916-9387","smeehan1@hfhs.org",{"name":56,"role":28,"phone":24,"phoneExt":24,"email":24},"Loay Kabbani, MD",{"facility":5,"status":58,"city":59,"state":40,"zip":60,"country":42,"countryCode":43,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"RECRUITING","Grand Rapids","49503",{"type":45,"coordinates":62},[63,64],-85.66809,42.96336,{"lat":64,"lon":63},[67],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},{"type":28,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Vikram Kashyap","Vice President, Cardiovascular Health, Frederik Meijer Heart and Vascular Institute",[72],{"name":37,"class":6},"100598791","phase-4-vascular-trial-associated-registry-pilot-100598791",false,"NCT07076082","Vascular Trial Associated Registry Pilot","Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization","VSTAR-P","Inclusion Criteria:\n\n* Age greater than or equal to 45 at time of enrollment\n* Patient is scheduled for a PVI or has recently had a PVI in the last 30 days\n* Patient data is being submitted to Fivos, who is acting as the data collection subcontractor for the VQI-PVI registry.\n* Atherosclerotic vascular disease\n\nExclusion Criteria:\n\n* Patients who cannot consent for themselves\n* Allergy to Clopidogrel\n* Patients unable to stop clopidogrel for other medical reasons\n* Patients on dual pathway inhibition (DPI) with low dose rivaroxaban (2.5mg twice a day) that are unable to stop these medications\n* Allergy to aspirin\n* Nonatherosclerotic vascular disease\n* Patients undergoing open bypass at the same time as the peripheral transcutaneous angioplasty\n* Patients with high bleeding risk (HBR) defined as:\n\n  * History of major bleeding, active bleeding disorder, severe renal impairment (CrCl \\\u003C30), concurrent anticoagulation, platelet count \\\u003C100,000\n  * Recent stroke (within 6 months)\n  * Current warfarin therapy or full dose therapeutic direct oral anticoagulants (DOAC).\n* Patients unwilling or unable to comply with standard of care follow-up visits\n* Pregnant women\n* Prisoners","ALL","45 Years",{"count":84,"type":85},350,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.",[91],"Peripheral Arterial Disease",[93],"Peripheral Vascular Disease (PVD), Peripheral Vascular Intervention (PVI), Dual Antiplatelet therapy (DAPT), Peripheral Arterial Disease (PAD)","2026-04-08",{"date":96,"type":97},"2026-04-13","ACTUAL",{"date":99,"type":97},"2025-10-15",{"date":101,"type":85},"2028-10-30",{"name":5,"class":6},2]